{
  "abstract": "India's approval of TAK-003 (Qdenga) on July 20, 2026, marks a defining moment in dengue prevention, yet four-serotype complexity demands a calibrated rather than uniform strategy. Built on a live-attenuated DENV-2 backbone, TAK-003 generates lower type-specific neutralising antibody titres - most critically against DENV-3 - an imbalance compounded by original antigenic sin, which may further limit cellular priming against DENV-3 and DENV-4. India's epidemiology amplifies these concerns: DENV-3 accounted for nearly 80% of typed cases in Bengaluru in 2024 - a regional signal, though serotype dominance varies across States - and large seronegative peri-urban populations remain vulnerable. NIH TV003-derived vaccines, including India's DengiAll in Phase 3, incorporate attenuated strains of all four serotypes, offering potentially broader immunity. TAK-003's demonstrated efficacy against severe dengue and hospitalisation - including in seronegative participants - makes it a valuable first-line tool. We argue for a phased, serotype-informed strategy: deploy TAK-003 now, while building surveillance capacity for vaccines with potentially broader serotype coverage.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Paediatrics, Mangla Hospital Research Centre, Bijnor, Uttar Pradesh, India.",
    "Department of Paediatrics, Kumar Child Clinic, New Delhi, India."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 2,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Vipin M Vashishtha"
    },
    {
      "affs": [
        1
      ],
      "name": "Puneet Kumar"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/em171vc7b867s.bib",
  "cited_by": 0,
  "doi": "10.25259/ijmr_1987_2026",
  "fulltext_url": "https://europepmc.org/articles/PMC13650901",
  "id": "em171vc7b867s",
  "issns": [
    "0971-5916"
  ],
  "landing_url": "https://europepmc.org/article/MED/42851221",
  "language": "eng",
  "licence": "CC-BY-NC-SA",
  "licence_label": "CC BY-NC-SA",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-sa/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2739|Mosquito-borne diseases and control"
    ]
  ],
  "openalex": "W7212351366",
  "pdf_url": "https://europepmc.org/articles/PMC13650901?pdf=render",
  "pmcid": "PMC13650901",
  "pmid": "42851221",
  "published": "2026-08-01",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/em171vc7b867s.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:18:10Z",
      "native_id": "MED:42851221",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42851221"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2739|Mosquito-borne diseases and control",
      "subfield": "epidemiology-public-health"
    }
  ],
  "title": "Dengue vaccines and serotype complexity: Why India needs a calibrated strategy.",
  "title_text": "Dengue vaccines and serotype complexity: Why India needs a calibrated strategy.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:18:10Z",
  "url": "https://research.draconitic.com/paper/em171vc7b867s",
  "venue": "The Indian journal of medical research",
  "versions": []
}